APOA1 and APOB polymorphisms and apolipoprotein concentrations as biomarkers of risk in acute coronary syndrome: Relationship with lipid-lowering therapy effectiveness

作者：Casillas Munoz Fidel; Valle Yeminia; Francisco Munoz Valle Jose; Emilia Martinez Fernandez Diana; Lizet Reynoso Villalpando Gabriela; Enrique Flores Salinas Hector; Anais Llamas Covarrubias Mara; Ramon Padilla Gutierrez Jorge

来源：Medicina Clinica, 2018, 151(1): 1-7.

DOI：10.1016/j.medcli.2017.07.026

• Acute coronary syndrome
• Atherogenic risk
• Apolipoprotein Al
• Apolipoprotein B
• Lipid-lowering therapy

Background and objective: Lipid metabolism alterations contribute to acute coronary syndrome (ACS). rs670, rs5070 and rs693 polymorphisms have shown to modify the risk of cardiovascular disease. Apolipoprotein A-I (ApoA-1) plays a major role in reverse cholesterol transport; apolipoprotein B (ApoB) contributes to accumulation of cholesterol in the plaque. The aim of this study was to investigate the association of rs670 and rs5070 polymorphisms of APOA1 and rs693 polymorphism of APOB with ACS and circulating levels of its proteins and find if ApoB/ApoA-I could be implemented as an independent parameter of risk for cardiovascular disease and as a biomarker of lipid-lowering therapy effectiveness in Mexican population.
Methods: Three hundred patients with ACS and 300 control subjects (CS) were included.
Results: Neither genotype nor allele frequencies of rs670, rs5070 and rs693 polymorphisms showed statistical differences between groups. Serum levels of ApoA-I (195 vs. 161.4 mg/dL; P< .001) and ApoB (167 vs. 136.9 mg/dL; P< .001) were significantly higher in CS compared with ACS; however, there was no genetic association. Unstable angina patients showed the highest ApoA-I levels (males: 176.3 mg/dL; females: 209.1 mg/dL).
Conclusion: The rs670, rs5070 and rs693 polymorphisms are not genetic susceptibility factors for ACS in Mexican population and had no effect on their apolipoprotein concentrations. In our population, ApoA-I, ApoB and HDL-C could be better biomarkers of cardiovascular risk and could indicate if statins doses reduce atherogenic particles properly.

• 出版日期2018-7-13